After 28 days of Ang II infusion, AAA occurred in the Ang II group with an incidence of 75.00% (9/12), and AB4 treatment inhibited the development of AAA with a decreased incidence of 41.67% (5/12) (Figures 1A, B). This evidence concerns the gene AGT and triple-A syndrome.